Scarica l'app Stockscreener
1.90
1.04%
-0.02
Precedente Chiudi:
$1.92
Aprire:
$1.92
Volume 24 ore:
1.10M
Relative Volume:
0.63
Capitalizzazione di mercato:
$127.28M
Reddito:
-
Utile/perdita netta:
$-122.44M
Rapporto P/E:
-0.8429
EPS:
-2.254
Flusso di cassa netto:
$-103.79M
1 W Prestazione:
+6.74%
1M Prestazione:
+18.75%
6M Prestazione:
-78.43%
1 anno Prestazione:
-48.37%
Intervallo 1D:
$1.85
$1.93
Intervallo di 1 settimana:
$1.7841
$1.96
Portata 52W:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Nome
Engene Therapeutics Inc
Settore
Industria
Telefono
(514) 332-4888
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.90 | 127.28M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | WBB Securities | Buy |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Iniziato | Piper Sandler | Overweight |
| 2025-02-14 | Downgrade | UBS | Buy → Neutral |
| 2024-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-27 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2024-04-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-03-28 | Iniziato | UBS | Buy |
| 2024-03-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Engene Therapeutics Inc Borsa (ENGN) Ultime notizie
Layoff Tracker: Novartis cuts New Jersey workforce again, ousting 322 employees - BioSpace
enGene reports 54% response rate in bladder cancer trial - Investing.com
Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN
enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView
enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView
Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz
Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView
ENGN Forecast — Price Target — Prediction for 2027 - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
enGene Therapeutics - The Business Journals
Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo
ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus
EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo
enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports
EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com
Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com
Morgan Stanley Downgrades EnGene Therapeutics(ENGN.US) to Sell Rating - Moomoo
Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com
Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK
enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan
enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan
enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan
[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan
enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan
Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan
Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN) - Stock Titan
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail
Guggenheim Maintains EnGene Therapeutics(ENGN.US) With Hold Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
EnGene slashes staff by 50% to preserve cash ahead of regulatory push - The Business Journals
ENGN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
enGene Restructures, Cuts Workforce to Advance Bladder Therapy - The Globe and Mail
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Engene stock price target on clinical setbacks - Investing.com
enGene Therapeutics reports Q2 2026 financial results - grafa.com
enGene (ENGN) Announces Workforce Reduction and Leadership Changes - GuruFocus
enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements – Minichart - Minichart
enGene Therapeutics (ENGN) Q2 2026 earnings summary - Quartr
Engene Therapeutics Inc Azioni (ENGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):